Abchurch has been appointed by Quantum Pharma Plc, (“Quantum”), a growing manufacturer, supplier and service provider to pharmaceutical wholesalers, retail pharmacy, hospitals, pharmaceutical companies, homecare and care home markets. Quantum has appointed Abchurch to advise on its Financial PR and its Investor Relations programme and its intention to seek admission of its shares to trading on the AIM Market of the London Stock Exchange. The Company has successfully raised £106.1 million giving it a market capitalisation of £125 million. Zeus Capital is acting as Nominated Adviser and Sole Broker to the Company.
The core business of the Group, Quantum Pharmaceutical, is the UK’s leading manufacturer and supplier of Specials and Special Obtains. It delivers its portfolio of 22,000 Special and Special Obtain products and regularly services around 6,500 pharmacies and over 240 hospitals accounts across the UK. The core division is complimented by four other divisions, UL Medicines, Colonis, Biodose and Quantum Aseptics.
Julian Bosdet, Senior Partner of Abchurch commented: “Quantum will be the largest AIM IPO in the pharmaceutical sector this year and we are delighted to be working alongside Zeus Capital and other leading advisors on such a substantial listing. Additionally, it is fantastic to complete our 80th successful IPO with such an exciting company. The team is delighted to work alongside Quantum to position the Group as a novel and innovative player in this exciting space. We look forward to working with the Company and its advisers going forward.”
- Ends -
Tel: +44 (0)20 7398 7701